Tools and methods for the detection or quantification of human cytomegalovirus (CMV) in a sample by means of amplification of human CMV nucleic acid.
Glycopeptides of the gcI (gB) complex of human cytomegalovirus are disclosed.
These compounds are useful for the treatment of human cytomegalovirus infection.
The present disclosure shows human cytomegalovirus (HCMV) is strongly associated with a variety of cancers in humans.
The present invention relates to a crystal structure of human cytomegalovirus protease (HCMV PR).
HCMV glycoproteins B and H have been identified.
The inventive peptides are used in the preparation of a medicaments for vaccination against HVMV infections or a diagnostic reagent for identifying an immune response against HCMV.
The novel vectors of the present invention comprise a promoter normally associated with the US3 gene of Human Cytomegalovirus (HCMV).
Disclosed according to the invention are immunogenic proteolytic fragments of a glycoprotein complex (gC-I) of human cytomegalovirus (HCMV).
Such agents may be used, for example, in the treatment of patients infected with HCMV.
There are currently eight species in this genus including the type species human herpesvirus 5 (HHV-5).
The eight species in this genus include the type species, Human betaherpesvirus 5 (HCMV, human cytomegalovirus, HHV-5), which is the species that infects humans.
There are currently eight species in this genus including the type species, human cytomegalovirus (HCMV, human herpesvirus 5, HHV-5), which is the species that infects humans.
There are currently eight species in this genus including the type species, Human betaherpesvirus 5 (HCMV, human cytomegalovirus, HHV-5), which is the species that Class: incertae sedis.
Such cell lines may be used, for example, for specifically identifying HCMV infection in a biological sample.
Human cytomegalovirus (HCMV) is the leading cause of congenital viral infection and mental retardation.
The present invention provides novel antibody sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection.
The present invention provides novel antibody sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection.
The present invention includes compositions and methods for the treatment and prevention of conditions associated with Human Cytomegalovirus (HCMV) infection.
A BTLA activating protein present in human cytomegalovirus is identified as UL144.
In particular embodiments, the chimeric promoter regulatory sequence comprises sequence elements derived from the murine or the human cytomegalovirus IE1 promoter and from the human and/or the simian cytomegalovirus IE1 region.
Methods for producing recombinant polypeptides which are immunological equivalents of human cytomegalovirus glycoprotein H are disclosed.
A substantially pure, immunogenic glycoprotein complex of human cytomegalovirus having a molecular weight greater than about 200 kD is disclosed.
Disclosed herein are antiviral compounds, such as anti-human cytomegalovirus antiviral compounds, pharmaceutical compositions and antiviral methods.
Disclosed are a cytomegalovirus human immunoglobulin for intravenous injection and a preparation method therefor.
The nucleoside analogs are effective against herpes simplex virus types 1 and 2; Epstein-Barr Virus and human cytomegalovirus.
The present invention provides a virus comprising a DNA sequence essential for replication of a human cytomegalovirus and at least one foreign DNA sequence adapted for expression in a host.
The invention shows the generation of a soluble peptide comprising the C-terminal region of the UL89 protein (UL89-C) of the human cytomegalovirus.
Molecular epidemiology of primary human cytomegalovirus infection in pregnant women and their families.
Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.
Disclosed is a novel and highly practically available means for detecting the infection with an HCMV with high sensitivity.
Diagnosis and Management of Human Cytomegalovirus Infection in the Mother, Fetus, and Newborn Infant
This disclosure provides anti-human cytomegalovirus antibodies and methods of treatment, prophylaxis, detection, and diagnosis using the same.
In particular, it has been recognized that the UL11 protein of human the cytomegalovirus, binds to the CD45 molecule, potentially altering the immune system of an individual.
Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells.
The invention provides expression vectors containing the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus.
The human cytomegalovirus (CMV) is globally widespread and the majority of adults are carriers, also in Germany.
The present invention provides an early structural gene of human cytomegalovirus (HCMV), and an envelope glycoprotein and its polypeptide precursor which are encoded by the early gene.
Disclosed is a pharmaceutical composition and a method for its use in the diagnosis and medical treatment of human cytomegalovirus infection.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод